Y-mabs announces frontline data for danyelza® (naxitamab-gqgk) in high-risk neuroblastoma

New york, june 04, 2021 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that dr. jaume mora, m.d., ph.d. from sjd barcelona children's hospital will present frontline data for danyelza and gm-csf for consolidation of high-risk neuroblastoma (“hr-nb”) patients in complete remission at the american society of clinical oncology (“asco”) virtual annual meeting on june 4, 2021
YMAB Ratings Summary
YMAB Quant Ranking